Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benzylidene-glucose: no effect after all?

G Tanum1, K M Tveit, H Høst

  • 1Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.

American Journal of Clinical Oncology
|April 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early-onset colorectal cancer incidence in Norway: a national registry-based study (1993-2022) analyzing subsite and morphology trends.

ESMO gastrointestinal oncology·2026
Same author

Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.

The pharmacogenomics journal·2015
Same author

Pericellular oxygen monitoring with integrated sensor chips for reproducible cell culture experiments.

Cell proliferation·2014
Same author

Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.

Molecular oncology·2013
Same author

Oxygen consumption in T-47D cells immobilized in alginate.

Cell proliferation·2013

Benzylidene-D-glucose (BG) showed no effectiveness in treating colorectal cancer patients. This phase II study did not confirm previous sensational findings, indicating BG is not an active agent for this cancer type.

Area of Science:

  • Oncology
  • Cancer Therapeutics
  • Clinical Pharmacology

Background:

  • Benzaldehyde derivatives have shown promise in human cancer treatment.
  • Benzylidene-D-glucose (BG) is a benzaldehyde derivative with previously reported sensational results.
  • The efficacy of BG in colorectal cancer requires further investigation.

Purpose of the Study:

  • To investigate and confirm the reported efficacy of benzylidene-D-glucose (BG) in colorectal cancer.
  • To evaluate the therapeutic potential of BG in patients with metastatic adenocarcinoma of the colon and rectum.

Main Methods:

  • A phase II clinical study was conducted.
  • Fourteen patients with metastatic colorectal adenocarcinoma received BG treatment.
  • Treatment duration was 8 weeks, followed by tumor response evaluation.

Related Experiment Videos

Main Results:

  • No clinical tumor regression was observed in any of the patients.
  • No significant side effects were reported during the treatment period.
  • The study failed to confirm the previously reported positive outcomes for BG.

Conclusions:

  • Benzylidene-D-glucose (BG) demonstrated no activity in the treatment of colorectal cancer.
  • The findings do not support the use of BG as a therapeutic agent for this patient population.
  • Further research into BG's role in cancer treatment is not warranted based on these results.